二甲双胍联合利拉鲁肽治疗肥胖2型糖尿病患者的临床疗效及安全性评价

Clinical Efficacy and Safety Evaluation of Metformin Combined with Liraglutide in the Treatment of Obese Patients with Type 2 Diabetes Mellitus

目的探究二甲双胍联合利拉鲁肽治疗肥胖2型糖尿病患者的临床疗效及安全性。方法选取2020年10月—2021年10月在该院接受治疗的60例肥胖2型糖尿病患者,随机分为单一组(n=30)与联合组(n=30)。在常规干预的同时单一组患者接受二甲双胍治疗,联合组患者接受二甲双胍联合利拉鲁肽治疗。比较两组患者FPG、2 hPG、HbA1c、HOMA-IR、HOMA-β、BMI、不良反应发生率等。结果治疗后,联合组患者的血糖水平指标(FPG、2 hPG、HbA1c)均低于于单一组,差异有统计学意义(P<0.05)。联合组患者的胰岛β细胞功能指数为(42.68±9.64),高于单一组的(35.49±8.77),差异有统计学意义(P<0.05);联合组患者的胰岛素抵抗指数、体质指数分别为(1.27±0.21)、(26.57±1.04)kg/m2,低于单一组的(1.53±0.39)、(27.25±1.21)kg/m2,差异有统计学意义(P<0.05)。单一组不良反应发生率为10.00%,联合组为3.33%,差异无统计学意义(P>0.05)。结论给予肥胖2型糖尿病患者二甲双胍联合利拉鲁肽进行治疗,临床疗效显著,可有效降低患者血糖水平,保护胰岛β细胞,改善胰岛素抵抗,减轻患者体质量,药物安全性良好。

Objective To investigate the clinical efficacy and safety of metformin combined with liraglutide in the treatment of obese patients with type 2 diabetes mellitus.Methods A total of 60 obese patients with type 2 diabetes who were treated in this hospital from October 2020 to October 2021 were selected and randomly divided into a single group(n=30)and a combined group(n=30).Patients in the single group received metformin therapy while routine intervention,and patients in the combined group received metformin combined with liraglutide.FPG,2 hPG,HbA1c,HOMA-IR,HOMA-βand BMI,the incidence of adverse reactions,etc.were compared between the two groups.Results After treatment,the blood glucose level indicators(FPG,2 hPG,HbA1c)in the combined group were lower than those in the single group,and the difference was statistically significant(P<0.05).The isletβ-cell function index of the combined group was(42.68±9.64),which was higher than that of the single group(35.49±8.77),and the difference was statistically significant(P<0.05);the insulin resistance index and body mass index of the patients in the combined group were(1.27±0.21)kg/m2 and(26.57±1.04)kg/m2,respectively,which were lower than those in the single group(1.53±0.39)kg/m2 and(27.25±1.21)kg/m2,and the differences were statistically significant(P<0.05).The incidence of adverse reactions in the single group was 10.00%,and that in the combined group was 3.33%,and the difference was not statistically significant(P>0.05).Conclusion The clinical efficacy of metformin combined with liraglutide in obese patients with type 2 diabetes mellitus is significant.It can effectively reduce the blood glucose level of patients,protect islet beta cells,improve islet function,reduce patient weight,and the drug safety is good.